A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 18 - 100 Years
Gender: Male or Female
Recruitment StatusEnrolling By Invitation
If you need help finding a study or have any questions, please contact us at email@example.com or by phone at (888) 264-0005.